We performed a retrospective assessment of patient-and transplant-specific characteristics
and outcomes for 4142 patients undergoing allogeneic haematopoietic cell transplant for …

Allogeneic hematopoietic stem cell transplant remains the only curative treatment for
myelofibrosis. Most post-transplantation events occur during the first two years and hence …

The number of patients with myelofibrosis (MF) undergoing an allogeneic hemopoietic stem
cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood …

Allogeneic haematopoietic stem‐cell transplantation (HSCT) is the only curative treatment
for myelofibrosis. We report an analysis of the Société Française de Greffe de Moelle et de …

New options for medical therapy and risk scoring systems containing molecular data are
leading to increased complexity in the management of patients with myelofibrosis. To inform …

Heterogeneous practices exist across transplant centres regarding assessment prior to
allogeneic haematopoietic cell transplantation (allo-HCT) for myelofibrosis, post-transplant …

The aim of this work is to produce recommendations on the management of allogeneic stem
cell transplantation (allo-SCT) in primary myelofibrosis (PMF). A comprehensive systematic …

This retrospective study by the European Society for Blood and Marrow Transplantation
analyzed the outcome of 2224 patients with myelofibrosis (MF) who underwent allogeneic …

Background Myelofibrosis is a myeloproliferative stem cell disorder curable exclusively by
allogeneic hematopoietic stem cell transplantation and is associated with substantial …

To develop a prognostic model for patients undergoing allogeneic hematopoietic cell
transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients …